Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Masuda

Showing results (191-200 of 249) with videos related to

Pageof 25
Sort By:
Asian Journal of Andrology|July 10, 2012
A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasiaYasukazu Nakanishi, Hitoshi Masuda, Satoru Kawakami, et al.
Anticancer Research|June 29, 2026
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell CarcinomaMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 23, 2025
Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approachKohei Hirose, Yasukazu Nakanishi, Ryo Andy Ogasawara, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
The Journal of Urology|April 2, 2013
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsyYoshinobu Komai, Noboru Numao, Soichiro Yoshida, et al.
JCO Clinical Cancer Informatics|June 30, 2026
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101Hiroshi Fukushima, Soichiro Yoshida, Shugo Yajima, et al.
Urology|July 15, 2026
Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY studyWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2012
Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancerSoichiro Yoshida, Fumitaka Koga, Shuichiro Kobayashi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|February 21, 2009
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]Hajime Tanaka, Hitoshi Masuda, Yoshinobu Komai, et al.
BJU International|August 16, 2014
Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsyYoh Matsuoka, Noboru Numao, Kazutaka Saito, et al.
Pageof 25

Showing results (191-200 of 249) with videos related to

Sort By:
Pageof 25
Asian Journal of Andrology|July 10, 2012
A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasiaYasukazu Nakanishi, Hitoshi Masuda, Satoru Kawakami, et al.
Anticancer Research|June 29, 2026
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell CarcinomaMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 23, 2025
Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approachKohei Hirose, Yasukazu Nakanishi, Ryo Andy Ogasawara, et al.
Japanese Journal of Clinical Oncology|January 16, 2026
Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancerKohei Hirose, Soichiro Yoshida, Wei Chen, et al.
The Journal of Urology|April 2, 2013
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsyYoshinobu Komai, Noboru Numao, Soichiro Yoshida, et al.
JCO Clinical Cancer Informatics|June 30, 2026
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101Hiroshi Fukushima, Soichiro Yoshida, Shugo Yajima, et al.
Urology|July 15, 2026
Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY studyWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2012
Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancerSoichiro Yoshida, Fumitaka Koga, Shuichiro Kobayashi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|February 21, 2009
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]Hajime Tanaka, Hitoshi Masuda, Yoshinobu Komai, et al.
BJU International|August 16, 2014
Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsyYoh Matsuoka, Noboru Numao, Kazutaka Saito, et al.
Pageof 25